摘要脉络膜新生血管(CNV)形成是新生血管性老年性黄斑变性(nAMD)的主要病理改变.针对CNV发生发展过程中具有重要作用的血管内皮细胞生长因子(VEGF)的各种眼内抗VEGF药物靶向治疗是目前nAMD治疗的一线选择.但如何以更低的治疗负担,进一步提高抑制CNV的持续有效性,获得更好的视功能改善仍然是nAMD药物治疗面临的挑战.抗VEGF药物缓释装置以及抗VEGF之外新的治疗策略探索是优化改进现有nAMD药物治疗方案的发展趋势,为充满挑战而任重道远的nAMD治疗研究治疗带来了又一轮曙光.

abstractsChoroidal neovascularization (CNV) is the key characteristic of neovascular age-related macular degeneration (nAMD),and the effective therapy is intravitreal injection of anti vascular endothelial growth factor (VEGF) agents based on clinical and basic research.In the meantime the challenge is how to further improve the inhibiting effect for CNV and visual function of anti-VEGF treatment on nAMD.The new strategy and drug delivery devices for anti-VEGF treatment will optimize the clinical scheme.From bench to bedside,the research on targeted treatment of angiogenesis brings the bloom of nAMD medical therapy.